BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amato MP, Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. CNS Drugs 2015;29:207-20. [PMID: 25773609 DOI: 10.1007/s40263-015-0238-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Anagnostouli M, Markoglou N, Chrousos G. Psycho-neuro-endocrino-immunologic issues in multiple sclerosis: a critical review of clinical and therapeutic implications. Hormones (Athens) 2020;19:485-96. [PMID: 32488815 DOI: 10.1007/s42000-020-00197-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Reyes MA, Vicuña J, Navas Á. Esclerosis múltiple y embarazo. Repertorio de Medicina y Cirugía 2016;25:33-9. [DOI: 10.1016/j.reper.2016.02.007] [Reference Citation Analysis]
3 Shirani A, Stüve O. Natalizumab: Perspectives from the Bench to Bedside. Cold Spring Harb Perspect Med 2018;8:a029066. [PMID: 29500304 DOI: 10.1101/cshperspect.a029066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
4 Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis. Expert Opin Drug Saf 2017;16:963-72. [PMID: 28641055 DOI: 10.1080/14740338.2017.1346082] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
5 Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. Neurology 2018;90:e832-9. [PMID: 29438041 DOI: 10.1212/WNL.0000000000005068] [Cited by in Crossref: 39] [Cited by in F6Publishing: 13] [Article Influence: 9.8] [Reference Citation Analysis]
6 Portaccio E, Pastò L, Razzolini L, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Gasperini C, Paolicelli D, Simone M, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Comi G, Filippi M, Trojano M, Amato MP. Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years. Mult Scler 2022;:13524585221079598. [PMID: 35296189 DOI: 10.1177/13524585221079598] [Reference Citation Analysis]
7 D'Aleo G, Rifici C, Donato A, Corallo F, Di Cara M, Bramanti P, Sessa E. Twin pregnancy outcome following teriflunomide treatment in a relapsing-remitting multiple sclerosis patient: A case report. Medicine (Baltimore) 2020;99:e21212. [PMID: 32664171 DOI: 10.1097/MD.0000000000021212] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Madsen C. The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis. Brain Behav 2017;7:e00696. [PMID: 28638705 DOI: 10.1002/brb3.696] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
9 Lavorgna L, Esposito S, Lanzillo R, Sparaco M, Ippolito D, Cocco E, Fenu G, Borriello G, De Mercanti S, Frau J, Capuano R, Trojsi F, Rosa L, Clerico M, Laroni A, Morra VB, Tedeschi G, Bonavita S. Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey. J Neurol 2019;266:707-16. [PMID: 30649617 DOI: 10.1007/s00415-019-09193-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Villaverde-González R. Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy. Degener Neurol Neuromuscul Dis 2022;12:1-21. [PMID: 35023987 DOI: 10.2147/DNND.S203406] [Reference Citation Analysis]
11 Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology 2018;90:e823-31. [PMID: 29438046 DOI: 10.1212/WNL.0000000000005067] [Cited by in Crossref: 49] [Cited by in F6Publishing: 17] [Article Influence: 12.3] [Reference Citation Analysis]
12 Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G. Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurol Sci 2017;38:1849-58. [PMID: 28770366 DOI: 10.1007/s10072-017-3081-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
13 Van Der Walt A, Nguyen A, Jokubaitis V. Family planning, antenatal and post partum care in multiple sclerosis: a review and update. Medical Journal of Australia 2019;211:230-6. [DOI: 10.5694/mja2.50113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Bonavita S, Lavorgna L, Worton H, Russell S, Jack D. Family Planning Decision Making in People With Multiple Sclerosis. Front Neurol 2021;12:620772. [PMID: 33995240 DOI: 10.3389/fneur.2021.620772] [Reference Citation Analysis]
15 Kamel FO. Factors Involved in Relapse of Multiple Sclerosis. J Microsc Ultrastruct 2019;7:103-8. [PMID: 31548920 DOI: 10.4103/JMAU.JMAU_59_18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
16 Tisovic K, Amezcua L. Women's Health: Contemporary Management of MS in Pregnancy and Post-Partum. Biomedicines 2019;7:E32. [PMID: 31010259 DOI: 10.3390/biomedicines7020032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
17 Vaughn C, Bushra A, Kolb C, Weinstock-Guttman B. An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis. CNS Drugs 2018;32:161-78. [PMID: 29508244 DOI: 10.1007/s40263-018-0496-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
18 Rosa GR, O'Brien AT, Nogueira EAG, Carvalho VM, Paz SC, Fragoso YD. There is no benefit in the use of postnatal intravenous immunoglobulin for the prevention of relapses of multiple sclerosis: findings from a systematic review and meta-analysis. Arq Neuropsiquiatr 2018;76:361-6. [PMID: 29972417 DOI: 10.1590/0004-282X20180041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
19 Filipi M, Jack S. Interferons in the Treatment of Multiple Sclerosis: A Clinical Efficacy, Safety, and Tolerability Update. Int J MS Care 2020;22:165-72. [PMID: 32863784 DOI: 10.7224/1537-2073.2018-063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Balakirski G, Gerdes S, Beissert S, Ochsendorf F, von Kiedrowski R, Wilsmann-Theis D. Therapy of psoriasis during pregnancy and breast-feeding. J Dtsch Dermatol Ges 2022;20:653-83. [PMID: 35578438 DOI: 10.1111/ddg.14789] [Reference Citation Analysis]
21 Balakirski G, Gerdes S, Beissert S, Ochsendorf F, von Kiedrowski R, Wilsmann-Theis D. Psoriasis-Therapie während Schwangerschaft und Stillzeit. J Dtsch Dermatol Ges 2022;20:653-85. [PMID: 35578434 DOI: 10.1111/ddg.14789_g] [Reference Citation Analysis]
22 De Giglio L, Grimaldi AE, Fubelli F, Marinelli F, Pozzilli C. Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis. Expert Rev Neurother 2019;19:417-29. [PMID: 31094239 DOI: 10.1080/14737175.2019.1610393] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Dumitrescu L, Constantinescu CS, Tanasescu R. Recent developments in interferon-based therapies for multiple sclerosis. Expert Opin Biol Ther 2018;18:665-80. [PMID: 29624084 DOI: 10.1080/14712598.2018.1462793] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
24 Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol 2016;23 Suppl 1:18-27. [PMID: 26563094 DOI: 10.1111/ene.12883] [Cited by in Crossref: 159] [Cited by in F6Publishing: 152] [Article Influence: 26.5] [Reference Citation Analysis]
25 Arneth BM. Pregnancy in patients with multiple sclerosis. J Investig Med 2021:jim-2020-001609. [PMID: 34385291 DOI: 10.1136/jim-2020-001609] [Reference Citation Analysis]
26 Alroughani R, Altintas A, Al Jumah M, Sahraian M, Alsharoqi I, AlTahan A, Daif A, Dahdaleh M, Deleu D, Fernandez O, Grigoriadis N, Inshasi J, Karabudak R, Taha K, Totolyan N, Yamout BI, Zakaria M, Bohlega S. Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. Mult Scler Int 2016;2016:1034912. [PMID: 28078140 DOI: 10.1155/2016/1034912] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
27 Colaceci S, Zambri F, Marchetti F, Trivelli G, Rossi E, Petruzzo A, Vanacore N, Giusti A. 'A sleeping volcano that could erupt sooner or later'. Lived experiences of women with multiple sclerosis during childbearing age and motherhood: A phenomenological qualitative study. Mult Scler Relat Disord 2021;51:102938. [PMID: 33882427 DOI: 10.1016/j.msard.2021.102938] [Reference Citation Analysis]
28 Coyle PK. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord 2016;9:198-210. [PMID: 27134675 DOI: 10.1177/1756285616631897] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 10.0] [Reference Citation Analysis]
29 Sadeghpour N, Mirmosayyeb O, Bjørklund G, Shaygannejad V. Is Fertility Affected in Women of Childbearing Age with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder? J Mol Neurosci 2020;70:1829-35. [PMID: 32740781 DOI: 10.1007/s12031-020-01576-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Hsu CN, Lin YJ, Yu HR, Lin IC, Sheen JM, Huang LT, Tain YL. Protection of Male Rat Offspring against Hypertension Programmed by Prenatal Dexamethasone Administration and Postnatal High-Fat Diet with the Nrf2 Activator Dimethyl Fumarate during Pregnancy. Int J Mol Sci 2019;20:E3957. [PMID: 31416234 DOI: 10.3390/ijms20163957] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
31 Massarotti C, Sbragia E, Boffa G, Vercelli C, Zimatore GB, Cottone S, Frau J, Raiola A, Varaldo R, Mancardi G, Inglese M, Anserini P. Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis. Mult Scler 2021;:13524585211000616. [PMID: 33709839 DOI: 10.1177/13524585211000616] [Reference Citation Analysis]
32 Kleerekooper I, van Kempen ZLE, Leurs CE, Dekker I, Rispens T, Lissenberg-Witte BI, van Munster CEP, de Jong BA, van Oosten BW, Uitdehaag BMJ, Wattjes MP, Killestein J. Disease activity following pregnancy-related discontinuation of natalizumab in MS. Neurol Neuroimmunol Neuroinflamm 2018;5:e424. [PMID: 29379823 DOI: 10.1212/NXI.0000000000000424] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
33 Gandhi S, Jakimovski D, Ahmed R, Hojnacki D, Kolb C, Weinstock-guttman B, Zivadinov R. Use of natalizumab in multiple sclerosis: current perspectives. Expert Opinion on Biological Therapy 2016;16:1151-62. [DOI: 10.1080/14712598.2016.1213810] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
34 Rasmussen PV, Magyari M, Moberg JY, Bøgelund M, Jensen UFA, Madsen KG. Patient awareness about family planning represents a major knowledge gap in multiple sclerosis. Mult Scler Relat Disord 2018;24:129-34. [PMID: 30005355 DOI: 10.1016/j.msard.2018.06.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
35 Kouri I, Mathews K, Joshi C. Facial Weakness and Ophthalmoplegia in a 4-Day-Old Infant. Semin Pediatr Neurol 2018;26:63-6. [PMID: 29961523 DOI: 10.1016/j.spen.2017.03.008] [Reference Citation Analysis]
36 Fabian M. Pregnancy in the Setting of Multiple Sclerosis. Continuum (Minneap Minn) 2016;22:837-50. [PMID: 27261685 DOI: 10.1212/CON.0000000000000328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
37 Gold R, Stefoski D, Selmaj K, Havrdova E, Hurst C, Holman J, Tornesi B, Akella S, McCroskery P. Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program. Neurol Ther 2016;5:169-82. [PMID: 27411694 DOI: 10.1007/s40120-016-0048-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
38 Almas S, Vance J, Baker T, Hale T. Management of Multiple Sclerosis in the Breastfeeding Mother. Mult Scler Int 2016;2016:6527458. [PMID: 26966579 DOI: 10.1155/2016/6527458] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
39 Zanghì A, D'Amico E, Callari G, Chisari CG, Borriello G, Grimaldi LME, Patti F. Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience. Front Neurol 2020;11:105. [PMID: 32158424 DOI: 10.3389/fneur.2020.00105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
40 Fragoso YD, Branco LP, de Carvalho VM. Pregnancy and Family Planning Considerations in Multiple Sclerosis. Curr Obstet Gynecol Rep. [DOI: 10.1007/s13669-022-00329-4] [Reference Citation Analysis]
41 Chisari CG, Toscano S, D’amico E, Lo Fermo S, Zanghì A, Arena S, Zappia M, Patti F. An update on the safety of treating relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety 2019;18:925-48. [DOI: 10.1080/14740338.2019.1658741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
42 Norborg H, Riise T, Myhr KM, Grytten N, Wergeland S. Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis. Mult Scler J Exp Transl Clin 2021;7:20552173211022027. [PMID: 34188949 DOI: 10.1177/20552173211022027] [Reference Citation Analysis]
43 Delbue S, Comar M, Ferrante P. Natalizumab treatment of multiple sclerosis: new insights. Immunotherapy 2017;9:157-71. [PMID: 28004598 DOI: 10.2217/imt-2016-0113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
44 Barataud-Reilhac A, Kerbrat S, Roux J, Guilleux A, Polard E, Leray E. Teriflunomide-exposed pregnancies in a French cohort of patients with multiple sclerosis. Neurol Clin Pract 2020;10:287-97. [PMID: 32983608 DOI: 10.1212/CPJ.0000000000000717] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
45 Hellwig K, Verdun di Cantogno E, Sabidó M. A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis. Ther Adv Neurol Disord 2021;14:17562864211051012. [PMID: 34876925 DOI: 10.1177/17562864211051012] [Reference Citation Analysis]
46 Comi G, Amato MP, Bertolotto A, Centonze D, De Stefano N, Farina C, Gallo P, Ghezzi A, Grimaldi LM, Mancardi G, Marrosu MG, Montanari E, Patti F, Pozzilli C, Provinciali L, Salvetti M, Tedeschi G, Trojano M. The heritage of glatiramer acetate and its use in multiple sclerosis. Mult Scler Demyelinating Disord 2016;1. [DOI: 10.1186/s40893-016-0010-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]